Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Akt
    (4)
  • Apoptosis
    (42)
  • Autophagy
    (16)
  • BCL
    (81)
  • Caspase
    (16)
  • ERK
    (4)
  • PARP
    (8)
  • PROTACs
    (6)
  • Parasite
    (5)
  • Others
    (132)
Filter
Search Result
Results for "BCL" in TargetMol Product Catalog
  • Inhibitor Products
    276
    TargetMol | Activity
  • Natural Products
    67
    TargetMol | inventory
  • Recombinant Protein
    34
    TargetMol | natural
  • Peptides Products
    21
    TargetMol | composition
  • PROTAC Products
    18
    TargetMol | Activity
  • Compound Libraries
    1
    TargetMol | inventory
  • Dye Reagents
    1
    TargetMol | natural
BCL6-IN-3
T104872253878-44-1
BCL6-IN-3 is a potent BCL6 inhibitor with GI50 of 70 nM in SU-DHL4 cells. BCL6-in-3 regulates cell activation, differentiation, DNA damage and apoptosis, and has antitumor activity.
  • $117
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Bcl-2-IN-16
T829102858632-01-4
Bcl-2-IN-16 is a Bcl-2 (B-cell lymphoma 2) inhibitor [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Bcl-2-IN-14
T82912
Bcl-2-IN-14 (Compound 13c), a BCL-2 inhibitor, exhibits an inhibitory concentration (IC 50) of 0.471 μM, and is applicable in cancer research [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Bcl-2-IN-12
T829141383737-59-4
Bcl-2-IN-12 (Compound 1) is a potent Bcl-2 inhibitor with an IC50 value of 6 nM, utilized in cancer research [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Bcl-2-IN-15
T82911
Bcl-2-IN-15 (Compound 13d) is a Bcl-2 inhibitor with an IC50 of 363 nM, which impedes the proliferation of the NCI leukemia cancer cell line [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Bcl-2-IN-5
T742982728752-20-1
Bcl-2-IN-5 is a potent inhibitor of BCL-2, demonstrating inhibitory concentrations (IC50) of 0.12 nM, 0.14 nM, and 0.22 nM against wild type Bcl-2, Bcl-2 D103Y, and Bcl-2 G101V, respectively. Additionally, it effectively suppresses cell growth in Bcl 2-G101V knock-in RS4;11 cells, with IC50 values of 0.2 nM and 0.44 nM.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Bcl-B inhibitor 1
T7757179220-88-5
Bcl-B inhibitor 1 is a Bcl-B inhibitor with antitumor activity that binds to and inactivates pro-apoptotic proteins in the BH3 structural domain.
  • $40
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Bcl-2-IN-13
T829131421687-31-1
Bcl-2-IN-13 is a potent inhibitor of Bcl-2, exhibiting an IC50 of 17 nM, and holds potential for use in cancer research [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Beclin1-Bcl-2 interaction inhibitor 1
T82902
Beclin1-Bcl-2 Interaction Inhibitor 1 effectively disrupts the binding of Beclin 1 to Bcl-2, and is utilized in cancer and neurodegeneration research [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
PROTAC Bcl-xL degrader-3
T739992471970-60-0
PROTAC Bcl-xL degrader-3 is a potent ROTAC Bcl-xL degrader.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Bcl-xL antagonist 2
T386221235032-75-3
Bcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
  • $147
In Stock
Size
QTY
TargetMol | Inhibitor Sale
MCL-1/BCL-2-IN-4
T119712163793-56-2
MCL-1/BCL-2-IN-4 is a selective and potent Mcl-1 and Bcl-2 dual inhibitor.
  • $1,520
6-8 weeks
Size
QTY
Bcl-2-IN-9
T637572490542-33-9
Bcl-2-IN-9 is a novel, pro-apoptotic, low cytotoxic Bcl-2 inhibitor (IC50: 2.9 μM). Bcl-2-IN-9 downregulates Bcl-2 expression, induces apoptosis in cancer cells, and exhibits high selectivity for leukemia cells.
  • $1,520
6-8 weeks
Size
QTY
TAT-BH4 (Bcl-xL) (TFA)
T80222
TAT-BH4 (Bcl-xL) TFA, primarily localized at the mitochondria, inhibits apoptotic cell death. This compound comprises an eosin-labeled cysteine at the N-terminal and the protein transduction domain from the HIV TAT protein (amino acids 49 to 57), fused to the Bcl-xL BH4 peptide. It is utilized in research concerning diseases associated with accelerated apoptosis [1].
  • Inquiry Price
Size
QTY
PROTAC Bcl-xL ligand-1
T74137
PROTAC Bcl-xL ligand-1 serves as a ligand targeting Bcl-xL, essential in synthesizing PROTACs [1].
  • Inquiry Price
Size
QTY
Bcl-2-IN-4
T742972703134-40-9
Bcl-2-IN-4, an orally active and selective inhibitor of Bcl-2, demonstrates potent efficacy with an IC50 value of 1.5 nM and exhibits more than 200-fold selectivity over Bcl-xL (IC50 of 411 nM). Additionally, it effectively inhibits the proliferation of RS4;11 cells, achieving an IC50 of 2.7 nM.
  • Inquiry Price
Size
QTY
PROTAC Bcl-xL degrader-1
T73957
PROTAC Bcl-xL degrader-1 is a potent PROTAC composed of a Bcl-xL (Bcl-2 family member) ligand-binding group, a linker, and an IAP E3 ligases binding group, demonstrating effectiveness as a Bcl-xL degrader. It exhibits toxicity towards human platelets and MyLa 1929 cells, with IC50 values of 62 nM and 8.5 μM, respectively [1].
  • Inquiry Price
Size
QTY
Bcl-2/Mcl-1-IN-3
T629412088981-53-5
Bcl-2/Mcl-1-IN-3 is a Bcl-2/Mcl-1 inhibitor that acts on Mcl-1 (Ki: 0.14 μM) and Bcl-2 (Ki: 0.23 μM) and can be used in cancer research.
  • $1,520
6-8 weeks
Size
QTY
Bcl-2/Mcl-1-IN-2
T624432673361-07-2
Bcl-2/Mcl-1-IN-2 is a Bcl-2 (Ki: 4.70 μM) and Mcl-1 (Ki: 0.88 μM) inhibitor.Bcl-2/Mcl-1-IN-2 can be used in cancer research.
  • $1,520
6-8 weeks
Size
QTY
CDK2/Bcl2-IN-1
T78813
CDK2/Bcl2-IN-1 (compound 1) is a saponin-based inhibitor of CDK-2 (IC50=117.6 nM) that exhibits potent cytotoxic effects on cancer cells. Additionally, it inhibits Bcl-2 and promotes apoptosis in A549 lung cancer cells [1].
  • Inquiry Price
Size
QTY
Lisaftoclax
T104832180923-05-9
Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells.
  • $187
In Stock
Size
QTY
PROTAC Bcl-xL degrader-2
T74138
PROTAC Bcl-xL degrader-2, based on von Hippel-Lindau ligand, is a potent degrader of Bcl-xL (a Bcl-2 family member), demonstrating an IC 50 of 0.6 nM.
  • Inquiry Price
Size
QTY
Bcl-2-IN-7
T63521
Bcl-2-IN-7 is a potent inhibitor of Bcl-2 (b-cell lymphoma-2), which can downregulate the expression of Bcl-2, increase the expression of p53, Bax, caspase-7 mRNA, and induce cell cycle arrest and apoptosis in MCF-7 cells of breast cancer. Bcl2-IN-7 showed good antitumor activity against MCF-7 cells (IC50: 20.17 μM), LoVo cells (IC50: 22.64 μM), HepG2 cells (IC50: 45.57 μM) and A549 cells (IC50: 51.50 μM).
  • $1,520
10-14 weeks
Size
QTY
Bcl-2-IN-6
T63676
Bcl-2-IN-6 is a potent inhibitor of Bcl-2 (b-cell lymphoma-2) that downregulates Bcl-2 expression and increases the expression of p53, Bax, and caspase-7 mRNA. bcl-2-IN-7 induces cell cycle arrest and apoptosis in breast cancer MCF-7 cells. bcl-2-IN-7 acts on MCF-7 cells ( Bcl2-IN-7 showed good antitumor effects on MCF-7 cells (IC50: 20.91 μM), LoVo cells (IC50: 22.30 μM), HepG2 cells (IC50: 42.29 μM) and A549 cells (IC50: 48.00 μM).
  • $1,520
10-14 weeks
Size
QTY
MCL-1/BCL-2-IN-2
T119692163793-44-8
MCL-1/BCL-2-IN-2 is a potent and selective Bcl-2 and Mcl-1 dual inhibitor.
  • $46
5 days
Size
QTY
TAT-BH4 (Bcl-xL)
T80221
TAT-BH4 (Bcl-xL), primarily localized at the mitochondria, inhibits apoptotic cell death. This compound comprises an N-terminal eosin-labeled cysteine and the protein transduction domain of the HIV TAT protein (amino acids 49 to 57), fused to the Bcl-xL BH4 peptide. It serves as a tool for research into diseases characterized by accelerated apoptosis [1].
  • Inquiry Price
Size
QTY
MCL-1/BCL-2-IN-3
T119702163793-55-1
MCL-1/BCL-2-IN-3 is a selective and potent Mcl-1 and Bcl-2 dual inhibitor with IC50s of 5.95 and 4.78 μM, respectiely.
  • $169
6-8 weeks
Size
QTY
MCL-1/BCL-2-IN-1
T119682493256-46-3
MCL-1/BCL-2-IN-2 (Compound Nap-1) is a potent and selective dual inhibitor of Mcl-1 and Bcl-2 with IC 50 s of 4.45 and 3.18 μM, respectively [1].
  • $1,110
10-14 weeks
Size
QTY
BCL6-IN-4
T364842253879-65-9
BCL6-IN-4, a potent inhibitor of B-cell lymphoma 6 (BCL6), exhibits anti-tumor activities with an inhibitory concentration 50 (IC50) value of 97 nM[1].
  • $1,900
8-10 weeks
Size
QTY
Bcl-2-IN-8
T64053
Bcl-2-IN-8 is a potent anti-cancer agent. bcl-2-IN-8 exhibits anti-proliferative effects on both drug-sensitive and drug-resistant cancer cells. bcl-2-IN-8 inhibits cell migration in a dose-dependent manner. bcl-2-IN-8 blocks the cell cycle in the G1 phase and induces apoptosis. bcl-2-IN-8 has shown research potential in triple-negative breast cancer. Bcl-2-IN-8 has shown potential for research in triple negative breast cancer.
  • $1,520
10-14 weeks
Size
QTY
BCL6-IN-6
T600082408882-54-0
BCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.
  • $69
In Stock
Size
QTY
Bcl-2-IN-11
T791712760536-88-5
Bcl-2-IN-11 (compound 6) is a potent and selective inhibitor of Bcl-2 activity, exhibiting an IC50 of 0.9 nM, and demonstrates minimal inhibition against Bcl-xl (IC50 > 1000 nM). This compound is utilized in researching various cancers linked to the overexpression of Bcl-2 family proteins, primarily malignant hematologic conditions such as acute lymphoid leukemia. Importantly, Bcl-2-IN-11 minimizes the risk of toxic side effects, including thrombocytopenia [1], by sparing Bcl-xl.
  • Inquiry Price
Size
QTY
Bcl-2-IN-2
T399612383085-86-5
Bcl-2-IN-2 is a highly potent and selective inhibitor targeting Bcl-2 and Bcl-xL. It displays an IC50 value of 0.034 nM, suggesting its strong inhibitory activity specifically against Bcl-2. Additionally, Bcl-2-IN-2 exhibits an IC50 value of 43 nM against Bcl-xL, demonstrating over 1000-fold selectivity for Bcl-2 compared to Bcl-xL.
  • $970
Backorder
Size
QTY
Bcl-2/Mcl-1-IN-1
T622492673361-08-3
Bcl-2/Mcl-1-IN-1 is an inhibitor of Bcl-2 (Ki: 4.53 μM) and Mcl-1 (Ki: 1.19 μM).Bcl-2/Mcl-1-IN-1 can be used in cancer research.
  • $1,520
6-8 weeks
Size
QTY
BCL6-IN-5
T397882253878-09-8
BCL6-IN-5 is a highly effective inhibitor of BCL6. It exhibits a pIC50 value of 5.82.
  • $332
5 days
Size
QTY
BCL6-IN-9
T628542378852-76-5
BCL6-IN-9 (compound 1) is a potent inhibitor of B-cell lymphoma 6 protein (BCL6) (IC50: 3.9 nM) and can be used to study cancer.
  • $2,140
10-14 weeks
Size
QTY
BCL6 PROTAC 1
T738692257479-54-0
BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) proteolysis targeting chimera (PROTAC) that inhibits the BCL6 cell reporter with an IC50 value of 8.8 µM and significantly degrades BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines, making it valuable for tumor-related research [1].
  • Inquiry Price
Size
QTY
Navitoclax
T2101923564-51-6
  • $41
In Stock
Size
QTY
TargetMol | Inhibitor Hot
S63845
T53461799633-27-4
S63845 is a selective MCL-1 inhibitor(Kd: 0.19 nM)
  • $79
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Venetoclax
T21191257044-40-8
Venetoclax (ABT-199) is a Bcl-2 inhibitor (Ki<0.01 nM) with potent, selective, and orally active properties. Venetoclax has a 3-order-of-magnitude lower affinity for Bcl-xL and Bcl-W (Kis=48/245 nM). Venetoclax induces autophagy and apoptosis.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
PROCYANIDIN C1
TN210337064-30-5
Procyanidin C1 is a natural product, with anti-inflammatory effects, and induces apoptosis.
  • $72
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
UMI-77
T6034518303-20-3
UMI-77, a specific Mcl-1 inhibitor (Ki: 490 nM), has selectivity over other members of Bcl-2 family.
  • $36
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Gossypol
T6518303-45-7
Gossypol (BL 193) Acetate is a polyphenolic aldehyde that permeates cells and acts as an inhibitor for several dehydrogenase enzymes.
  • $35
In Stock
Size
QTY
magnolin
T385731008-18-1
Magnolin reduces the renal oxidative stress, suppresses caspase-3 activity, and increases Bcl-2 expression in vivo and in vitro. Magnolin has anti-inflammatory and antioxidative effects.
  • $93
In Stock
Size
QTY
Vanillyl Alcohol
T2860498-00-0
Vanillyl Alcohol (3-Methoxy-4-hydroxybenzyl alcohol) possesses anti-angiogenic, anticonvulsive, anti-inflammatory, anti-oxidant, neuroprotective, and anti-nociceptive activities. Vanillyl alcohol can effectively inhibit the cytotoxicity and improved cell viability in 1-methyl-4-phenylpyridinium (MPP+)-induced MN9D dopaminergic cells, it also can attenuate the elevation of reactive oxygen species (ROS) levels, decrease in the Bax/Bcl-2 ratio and poly (ADP-ribose) polymerase proteolysis.
  • $42
In Stock
Size
QTY
BAD (103-127) (human) acetate
T40412L
BAD (103-127) (human) acetate is a 25-mer Bad polypeptide from the BAD BH3 domain that antagonizes the effects of Bcl-xl.
  • $195
In Stock
Size
QTY
NSC 122393
T83636L73654-97-4In house
NSC 122393 is a fluorescent dye that inhibits the interaction between Bax and Bcl-X and induces apoptosis in Bcl-X overexpressing breast cancer cells.
  • $195
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TV 3279
T77332209394-29-6In house
TV 3279 is a novel ChE-MAI inhibitor , and the neuroprotective properties depend on their ability to induce the anti-apoptotic proteins PKC, Bcl-2, Bcl-x, and SOD, and to block the nuclear translocation of the pro-apoptotic enzyme glyceraldehyde phosphate dehydrogenase in PC-12 and neuroblastoma cells.
  • $195
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Nitroaspirin
T16328175033-36-0
Nitroaspirin (NCX 4016) is a nitric oxide donor and a nitro-derivative of Aspirin, which combines with Nitroaspirin to inhibit cyclooxygenase. Nitroaspirin induces significant induction of cell cycle arrest and apoptosis in Cisplatin-resistant human ovarian cancer cells via down-regulation of EGFR/PI3K/STAT3 signaling and modulation of Bcl-2 family proteins. Nitroaspirin has antithrombotic and antiplatelet properties and acts as a direct and irreversible inhibitor of COX-1.
  • $148
In Stock
Size
QTY
Motixafortide TFA(664334-36-5,Free)
T14665L
Motixafortide TFA(664334-36-5,Free) (BKT140 TFA) is an antagonist of CXCR4 with IC50 of ~1 nM. It induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
  • $117
In Stock
Size
QTY